Liver Metastases clinical trials at University of California Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
Our lead scientists for Liver Metastases research studies include Nicholas Fidelman.